Evidence map›Paper›PMID 41017580›Full record

ArticleFuture oncology (London, England)2025

Programmed cell death ligand 1 (PD-L1) inhibitors versus programmed cell death 1 (PD-1) inhibitors for the first-line therapy of extensive-stage small cell lung cancer: a propensity score-matched study.

Zhuoran Sun, Yingfan Guo, Shuangqing Lu, Jiling Niu, Qinhao Xu, Hui Zhu, Yaru Tian

Abstract readMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhuoran SunDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China.
Yingfan GuoDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China.
Shuangqing LuShandong Provincial Key Laboratory of Precision Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Jiling NiuDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China.
Qinhao XuDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China.
Hui ZhuDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China.
Yaru TianDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe clinical efficacy and safety differences between PD-L1 inhibitors and PD-1 inhibitors remain controversial for ES-SCLC. We conduct the retrospective study and propensity score-matched analysis to explore the potential differences between them.

methodsThis retrospective study analyzed 736 ES-SCLC patients from three centers treated with EP plus either a PD-L1 or PD-1 inhibitor. According to PD-L1 or PD-1 inhibitors, they were divided into two groups. Propensity score matching (PSM, 1:1) was performed to balance the baseline characteristics of the two groups. The primary endpoints were OS and PFS.

resultsAs a result, 485 patients received PD-L1 inhibitors plus EP and 251 received PD-1 inhibitors plus EP. Before PSM, the PD-1 inhibitor group showed a significantly longer PFS (8.26 vs. 7.44 months; HR 1.252, p = 0.007), but no significant OS difference (20.30 vs. 18.85 months; p = 0.337). After PSM, both median OS (22.43 vs. 20.69 months) and PFS (8.23 months for both) were comparable, with no statistical differences (OS: HR 0.938, p = 0.613; PFS: HR 1.008, p = 0.940). Safety profiles were similar between groups.

conclusionsIn conclusion, the overall efficacy and safety profile were similar between PD-L1 inhibitors and PD-1 inhibitors for the first-line treatment of ES-SCLC.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenImmune Checkpoint InhibitorsLung NeoplasmsProgrammed Cell Death 1 ReceptorSmall Cell Lung CarcinomaAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeoplasm StagingPropensity ScoreRetrospective StudiesB7-H1 AntigenCD274 protein, humanImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorExtensive‐stage small cell lung cancer (ES‐SCLC)overall survival (OS)programmed death 1 (PD‐1) inhibitorsprogrammed death ligand 1 (PD‐L1) inhibitorspropensity score-matched study

Identifiers

PMID41017580
PMCPMC12536782

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.